secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coherus Oncology, Inc. (CHRS)
CIK:        0001512762
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001558370-24-007622
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coherus Q1 revenue $77.1M, net income $102.9M; UDENYCA +63% YoY; LOQTORZI launch underway
--------------------------------------------------------------------------------

- Net revenue $77.1M in Q1 2024 vs $32.4M in Q1 2023; GAAP net income $102.9M ($0.83 diluted EPS) vs net loss of $75.7M.
- UDENYCA net sales $42.7M, up 18% QoQ and 63% YoY; LOQTORZI launch sales $2.0M; CIMERLI divested for $187.8M cash.
- Non-GAAP net loss $35.8M (-$0.32 per share), improved from non-GAAP net loss $59.5M in Q1 2023.
- New debt and royalty financing replaces $75M term loan; debt maturity extended to May 2029.
- Entered partnership with CRI and ENB Therapeutics to study toripalimab in ovarian cancer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/0001558370-24-007622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1512762/000155837024007622/chrs-20240509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-007622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer